Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a

1 Feb 2024

Abstract excerpt

T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38367616
DOI: 10.1016/j.cell.2024.01.037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2aPMID 38367616Read ↗

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.Semantic proximity Read ↗

Type I interferons sensitise HIV-1-reactivating T-cells for NK cell-mediated elimination despite HDACi-imposed dysregulation of innate immunitySemantic proximity Read ↗

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialSemantic proximity Read ↗

Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency ReversalSemantic proximity Read ↗

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategiesSemantic proximity Read ↗

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapySemantic proximity Read ↗

The EZH2 inhibitor tazemetostat mitigates HIV immune evasion, reduces reservoir formation, and promotes durable CD8⁺ T-cell revitalizationSemantic proximity Read ↗

EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes.Semantic proximity Read ↗

Epigenetic control of HIV-1 post integration latency: implications for therapySemantic proximity Read ↗

Multi-Omics Single-Cell Analysis Reveals Key Regulators of HIV-1 Persistence and Aberrant Host Immune Responses in Early InfectionSemantic proximity Read ↗

Genome-wide analysis of histone modifications in latently HIV-1 infected T cellsSemantic proximity Read ↗

Therapy for Latent HIV-1 Infection: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.